Novartis (NVS) to Report Q1 Earnings: What to Expect?

Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS

Loads of analysts cut their price targets on these 10 stocks ahead of earnings

Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Novartis (NVS) to Undertake Job Cuts in Development Department

Novartis (NVS) Stock Sinks As Market Gains: Here's Why

Novartis (NVS) Declines More Than Market: Some Information for Investors

Novartis (NVS) Declines More Than Market: Some Information for Investors

15 Biggest Swiss Companies

Investors Heavily Search Novartis AG (NVS): Here is What You Need to Know

Investors Heavily Search Novartis AG (NVS): Here is What You Need to Know

Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know

Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

Novartis (NVS) Declines More Than Market: Some Information for Investors

Novartis (NVS) Declines More Than Market: Some Information for Investors

Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)

Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know

Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know